Literature DB >> 23143363

Risk factors for gastrointestinal tract colonization with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella species in hospitalized patients.

Jennifer H Han1, Irving Nachamkin, Theoklis E Zaoutis, Susan E Coffin, Darren R Linkin, Neil O Fishman, Mark G Weiner, Baofeng Hu, Pam Tolomeo, Ebbing Lautenbach.   

Abstract

We describe the prevalence of and risk factors for colonization with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella species (ESBL-EK) in hospitalized patients. The prevalence of colonization with ESBL-EK was 2.6%. Colonization was associated with cirrhosis, longer duration of hospital stay prior to surveillance, and prior exposure to clindamycin or meropenem.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23143363      PMCID： PMC3983276          DOI： 10.1086/668443

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


  9 in total

1.  Control of Enterobacteriaceae producing extended-spectrum beta-lactamase in intensive care units: rectal screening may not be needed in non-epidemic situations.

Authors:  Michelle Thouverez; Daniel Talon; Xavier Bertrand
Journal:  Infect Control Hosp Epidemiol       Date:  2004-10       Impact factor: 3.254

2.  Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae.

Authors:  Mitchell J Schwaber; Shiri Navon-Venezia; Keith S Kaye; Ronen Ben-Ami; David Schwartz; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.

Authors:  Mario Tumbarello; Maurizio Sanguinetti; Eva Montuori; Enrico M Trecarichi; Brunella Posteraro; Barbara Fiori; Rita Citton; Tiziana D'Inzeo; Giovanni Fadda; Roberto Cauda; Teresa Spanu
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

4.  Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit.

Authors:  C Peña; M Pujol; A Ricart; C Ardanuy; J Ayats; J Liñares; F Garrigosa; J Ariza; F Gudiol
Journal:  J Hosp Infect       Date:  1997-01       Impact factor: 3.926

5.  Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia.

Authors:  P Reddy; M Malczynski; A Obias; S Reiner; N Jin; J Huang; G A Noskin; T Zembower
Journal:  Clin Infect Dis       Date:  2007-08-20       Impact factor: 9.079

6.  Prevalence of CTX-M beta-lactamases in Philadelphia, Pennsylvania.

Authors:  Shannon E McGettigan; Baofeng Hu; Kathleen Andreacchio; Irving Nachamkin; Paul H Edelstein
Journal:  J Clin Microbiol       Date:  2009-07-08       Impact factor: 5.948

7.  Prospective evaluation of colonization with extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing enterobacteriaceae among patients during hospitalization.

Authors:  Reuven Friedmann; David Raveh; Esther Zartzer; Bernard Rudensky; Ellen Broide; Denise Attias; Amos M Yinnon
Journal:  Infect Control Hosp Epidemiol       Date:  2009-06       Impact factor: 3.254

8.  Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study.

Authors:  Kyoung-Ho Song; Jae Hyun Jeon; Wan Beom Park; Sang-Won Park; Hong Bin Kim; Myoung-don Oh; Hyo-Suk Lee; Nam Joong Kim; Kang Won Choe
Journal:  BMC Infect Dis       Date:  2009-04-12       Impact factor: 3.090

9.  Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission.

Authors:  Anthony D Harris; Jessina C McGregor; Judith A Johnson; Sandra M Strauss; Anita C Moore; Harold C Standiford; Joan N Hebden; J Glenn Morris
Journal:  Emerg Infect Dis       Date:  2007-08       Impact factor: 6.883
  9 in total
  12 in total

1.  Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia.

Authors:  Alan E Gross; Trevor C Van Schooneveld; Keith M Olsen; Mark E Rupp; Thu Hong Bui; Elsie Forsung; Andre C Kalil
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

2.  Systematic analysis of the relationship between antibiotic use and extended-spectrum beta-lactamase resistance in Enterobacteriaceae in a French hospital: a time series analysis.

Authors:  M-A Vibet; J Roux; E Montassier; S Corvec; M-E Juvin; C Ngohou; D Lepelletier; E Batard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-07-24       Impact factor: 3.267

3.  Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

Authors:  Pranita D Tamma; Jennifer H Han; Clare Rock; Anthony D Harris; Ebbing Lautenbach; Alice J Hsu; Edina Avdic; Sara E Cosgrove
Journal:  Clin Infect Dis       Date:  2015-01-13       Impact factor: 9.079

4.  Intestinal colonization with resistant bacteria: a prognostic marker of mortality in decompensated cirrhosis.

Authors:  S Pouriki; G Vrioni; H Sambatakou; A Alexopoulou; L Vasilieva; I Mani; A Tsakris; S P Dourakis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-09-30       Impact factor: 3.267

5.  Comparative Effectiveness of Ceftriaxone plus Metronidazole versus Anti-Pseudomonal Antibiotics for Perforated Appendicitis in Children.

Authors:  Rana F Hamdy; Lori K Handy; Evangelos Spyridakis; Daniele Dona; Matthew Bryan; Joy L Collins; Jeffrey S Gerber
Journal:  Surg Infect (Larchmt)       Date:  2019-03-15       Impact factor: 2.150

6.  Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.

Authors:  E-J Joo; D A Park; N R Lee; S-Y Moon; J-K Choi; J-H Ko; K R Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-23       Impact factor: 3.267

7.  Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital.

Authors:  Xiujuan Meng; Sidi Liu; Juping Duan; Xun Huang; Pengcheng Zhou; Xinrui Xiong; Ruie Gong; Ying Zhang; Yao Liu; Chenchao Fu; Chunhui Li; Anhua Wu
Journal:  BMC Infect Dis       Date:  2017-01-17       Impact factor: 3.090

8.  Gastrointestinal Tract Colonization Rate of Extended-Spectrum Beta-Lactamase- and Carbapenemase-Producing Enterobacteriaceae and Associated Factors Among Hospitalized Patients in Arba Minch General Hospital, Arba Minch, Ethiopia.

Authors:  Addis Aklilu; Aseer Manilal; Gemechu Ameya; Melat Woldemariam; Munira Siraj
Journal:  Infect Drug Resist       Date:  2020-05-22       Impact factor: 4.003

9.  Carriage of extended-spectrum beta-lactamase-producing enterobacteriacae among internal medicine patients in Switzerland.

Authors:  Janet Pasricha; Thibaud Koessler; Stephan Harbarth; Jacques Schrenzel; Véronique Camus; Gilles Cohen; Arnaud Perrier; Didier Pittet; Anne Iten
Journal:  Antimicrob Resist Infect Control       Date:  2013-06-12       Impact factor: 4.887

10.  High Gastrointestinal Colonization Rate with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Hospitalized Patients: Emergence of Carbapenemase-Producing K. pneumoniae in Ethiopia.

Authors:  Kassu Desta; Yimtubezinash Woldeamanuel; Aklilu Azazh; Halima Mohammod; Dawit Desalegn; Damte Shimelis; Dereje Gulilat; Biruk Lamisso; Eyasu Makonnen; Alemayehu Worku; Kerstin Mannerqvist; Johan Struwe; Olov Aspevall; Eleni Aklillu
Journal:  PLoS One       Date:  2016-08-30       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.